Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy

Detalles Bibliográficos
Autores principales: Fu, Yulong, Wang, Anqi, Zhou, Jieqi, Feng, Wei, Shi, Minhua, Xu, Xiao, Zhao, Hongqing, Cai, Liming, Feng, Jian, Lv, Xuedong, Zhang, Xiaodong, Xu, Wenjing, Zhang, Zhengrong, Ma, Guoer, Wang, Jian, Zhou, Tong, Zhao, Dahai, Fang, Haohui, Liu, Zeyi, Huang, Jian-an
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335792/
https://www.ncbi.nlm.nih.gov/pubmed/37441428
http://dx.doi.org/10.3389/fonc.2023.1236311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335792/
https://www.ncbi.nlm.nih.gov/pubmed/37441428
http://dx.doi.org/10.3389/fonc.2023.1236311

Ejemplares similares